Oral diabetes medications for adults with type 2 diabetes: an update

Bennett WL, Wilson LM, Bolen S, Maruthur N, Singh, S, Chatterjee R, Marinopoulos SS, Puhan MA, Ranasinghe P, Nicholson WK, Block L, Odelola O, Dalal DS, Ogbeche GE, Chandrasekhar A, Hutfless S, Bass EB, Segal JB
Record ID 32011001005
English
Authors' objectives:

Given the number of medications available for type 2 diabetes mellitus, clinicians and patients need information about their effectiveness and safety to make informed choices. The
objective of this review was to summarize the benefits and harms of medications (metformin, second-generation sulfonylureas, thiazolidinediones, meglitinides, dipeptidyl peptidase-4 [DPP-4] inhibitors, and glucagon-like peptide-1 [GLP-1] receptor agonists), as monotherapy and in combination, for the treatment of adults with type 2 diabetes.

Authors' recommendations: Comprehensive information comparing benefits and harms of diabetes medications can facilitate personalized treatment choices for patients. Although the long-term benefits andharms of diabetes medications remain unclear, the evidence supports use of metformin as a firstline agent. Comparisons of two-drug combinations showed little to no difference in HbA1c reduction, but some combinations increased risk for hypoglycemia and other adverse events.
Details
Project Status: Completed
URL for project: http://www.ncbi.nlm.nih.gov/books/NBK55754/pdf/TOC.pdf
Year Published: 2011
URL for published report: http://www.effectivehealthcare.ahrq.gov/index.cfm/search-for-guides-reviews-and-reports/?pageaction=displayproduct&productid=645
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: United States
MeSH Terms
  • Administration, Oral
  • Adult
  • Diabetes Mellitus, Type 2
Contact
Organisation Name: Agency for Healthcare Research and Quality
Contact Address: Center for Outcomes and Evidence Technology Assessment Program, 540 Gaither Road, Rockville, MD 20850, USA. Tel: +1 301 427 1610; Fax: +1 301 427 1639;
Contact Name: martin.erlichman@ahrq.hhs.gov
Contact Email: martin.erlichman@ahrq.hhs.gov
Copyright: Agency for Healthcare Research and Quality (AHRQ)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.